Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 1;110(11):2827-2833.
doi: 10.3324/haematol.2025.287485. Epub 2025 May 29.

MATRix and HD-MTX/IFO/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis

Fleur A De Groot  1 , Floriske G Stedema  2 , Esther J Kret  1 , Lorraine M De Haan  3 , Patty M Jansen  3 , Stefan Böhringer  4 , Arjan Diepstra  5 , Marjolein W M Van der Poel  6 , Myrurgia Abdul Hamid  7 , Liane C J Te Boome  8 , Valeska Terpstra  9 , Mirian Brink  10 , Hendrik Veelken  1 , Ruben A L De Groen  1 , Tim J A Dekker  1 , Marcel Nijland  2 , Joost S P Vermaat  11
Affiliations

MATRix and HD-MTX/IFO/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis

Fleur A De Groot et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Evaluation of survival outcomes following induction and autologous stem cell transplantation consolidation treatment and non-relapsed mortality analysis. (A) Progression-free survival (PFS) and overall survival (OS) of the complete cohort. (B) PFS and OS of patients treated with high-dose methotrexate, cytarabine, rituximab and thiotepa (MATRix) + autologous stem cell transplantation (ASCT) or high-dose methotrexate, ifosfamide and liposomal cytarabine (HD-MTX/IFO/DEP) + ASCT. (C) PFS and OS of patients who did or did not receive consolidation. (D) Non-relapsed mortality plot of patients treated with MATRix+ASCT or HD-MTX/IFO/DEP+ASCT. (E) OS and PFS Cox proportional hazards model including age, lactate dehydrogenase level at diagnosis, time to relapse, subtype of secondary central nervous system diffuse large B-cell lymphoma, induction treatment and ASCT consolidation with consolidation as a time-dependent variable. LDH: lactate dehydrogenase; SCNSL: secondary central nervous system lymphoma; C-SCNSL: concurrent central nervous system and systemic relapse of lymphoma; I-SCNSL: isolated central nervous system relapse of systemic lymphoma.
Figure 2.
Figure 2.
Swimmer plot of patients treated with high-dose methotrexate, ifosfamide and liposomal cytarabine + autologous stem cell transplantation or high-dose methotrexate, cytarabine, rituximab and thiotepa + autologous stem cell transplantation. HD-MTX/IFO/DEP+ASCT: high-dose methotrexate, ifosfamide, liposomal cytarabine + autologous stem cell transplantation; MATRix+ASCT: high-dose methotrexate, cytarabine, rituximab and thiotepa + autologous stem cell transplantation; R-CHOP+HD-MTX: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + high-dose methotrexate.
See this image and copyright information in PMC

References

    1. Korfel A, Elter T, Thiel E, et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 2013;98(3):364-370. - PMC - PubMed
    1. Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217-227. - PubMed
    1. Cwynarski K, Cummin T, Osborne W, et al. Management of secondary central nervous system lymphoma. Br J Haematol. 2023;200(2):160-169. - PubMed
    1. El-Galaly TC, Cheah CY, Bendtsen MD, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer. 2018;93:57-68. - PMC - PubMed
    1. Treiber H, Nilius-Eliliwi V, Seifert N, et al. Treatment strategies and prognostic factors in secondary central nervous system lymphoma: a multicenter study of 124 patients. Hemasphere. 2023;7(8):e926. - PMC - PubMed

LinkOut - more resources